Free Trial

Acumen Pharmaceuticals (ABOS) Competitors

$2.87
-0.06 (-2.05%)
(As of 07/19/2024 ET)

ABOS vs. BMEA, PRTK, ATHA, CHMA, EPZM, ARCT, ALMS, CGC, ESPR, and EDIT

Should you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include Biomea Fusion (BMEA), Paratek Pharmaceuticals (PRTK), Athira Pharma (ATHA), Chiasma (CHMA), Epizyme (EPZM), Arcturus Therapeutics (ARCT), Alumis (ALMS), Canopy Growth (CGC), Esperion Therapeutics (ESPR), and Editas Medicine (EDIT). These companies are all part of the "medical" sector.

Acumen Pharmaceuticals vs.

Biomea Fusion (NASDAQ:BMEA) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, community ranking, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Biomea Fusion had 2 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 2 mentions for Biomea Fusion and 0 mentions for Acumen Pharmaceuticals. Biomea Fusion's average media sentiment score of 1.48 beat Acumen Pharmaceuticals' score of 0.32 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Biomea Fusion Neutral
Acumen Pharmaceuticals Positive

Biomea Fusion has a beta of -0.53, meaning that its stock price is 153% less volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.1, meaning that its stock price is 90% less volatile than the S&P 500.

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 27.6% of Biomea Fusion shares are held by insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Biomea Fusion currently has a consensus price target of $28.25, suggesting a potential upside of 460.52%. Acumen Pharmaceuticals has a consensus price target of $12.00, suggesting a potential upside of 318.12%. Given Acumen Pharmaceuticals' higher probable upside, equities analysts plainly believe Biomea Fusion is more favorable than Acumen Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biomea Fusion
0 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.63
Acumen Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biomea FusionN/AN/A-$117.25M-$3.57-1.41
Acumen PharmaceuticalsN/AN/A-$52.37M-$1.06-2.71

Biomea Fusion's return on equity of -22.88% beat Acumen Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Biomea FusionN/A -69.88% -60.44%
Acumen Pharmaceuticals N/A -22.88%-20.82%

Biomea Fusion received 19 more outperform votes than Acumen Pharmaceuticals when rated by MarketBeat users. However, 65.52% of users gave Acumen Pharmaceuticals an outperform vote while only 61.29% of users gave Biomea Fusion an outperform vote.

CompanyUnderperformOutperform
Biomea FusionOutperform Votes
38
61.29%
Underperform Votes
24
38.71%
Acumen PharmaceuticalsOutperform Votes
19
65.52%
Underperform Votes
10
34.48%

Summary

Acumen Pharmaceuticals beats Biomea Fusion on 8 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABOS vs. The Competition

MetricAcumen PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$172.43M$2.97B$5.33B$8.23B
Dividend YieldN/A2.07%2.75%3.95%
P/E Ratio-2.7126.66138.5418.24
Price / SalesN/A251.192,144.6375.95
Price / CashN/A177.2536.3933.93
Price / Book0.623.874.874.42
Net Income-$52.37M-$44.32M$111.99M$216.15M
7 Day Performance1.77%-2.29%-0.66%-0.11%
1 Month Performance24.24%1.55%7.25%5.51%
1 Year Performance-61.22%-9.13%6.30%1.70%

Acumen Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMEA
Biomea Fusion
3.3068 of 5 stars
3.31 / 5 stars
$5.29
+6.7%
$28.25
+434.0%
-76.3%$190.12MN/A-1.48110Gap Up
PRTK
Paratek Pharmaceuticals
0.0077 of 5 stars
0.01 / 5 stars
$2.23
+1.8%
$2.15
-3.6%
+1.8%$127.82M$160.27M-2.03268Analyst Forecast
News Coverage
High Trading Volume
ATHA
Athira Pharma
2.9355 of 5 stars
2.94 / 5 stars
$3.32
+0.9%
$19.00
+472.3%
-1.6%$127.26MN/A-1.0965Short Interest ↑
News Coverage
CHMA
Chiasma
0 of 5 stars
0.00 / 5 stars
$3.76
flat
N/A+0.0%$217.68M$1.11M-2.3485Analyst Forecast
EPZM
Epizyme
0 of 5 stars
0.00 / 5 stars
$1.47
flat
N/A+0.0%$247.44M$37.43M-0.85250Analyst Forecast
ARCT
Arcturus Therapeutics
2.0809 of 5 stars
2.08 / 5 stars
$23.16
-2.5%
$64.86
+180.0%
-30.4%$623.70M$169.93M-5.92180Short Interest ↑
News Coverage
ALMS
Alumis
0 of 5 stars
0.00 / 5 stars
$11.09
-10.3%
N/AN/A$517.13MN/A0.00N/APositive News
Gap Down
CGC
Canopy Growth
1.1248 of 5 stars
1.12 / 5 stars
$6.50
+0.3%
$4.53
-30.3%
+82.8%$495.30M$220.27M-1.021,029News Coverage
Positive News
ESPR
Esperion Therapeutics
4.3389 of 5 stars
4.34 / 5 stars
$2.51
+0.8%
$8.83
+251.9%
+59.3%$475.55M$116.33M-2.54200Short Interest ↓
Positive News
EDIT
Editas Medicine
4.592 of 5 stars
4.59 / 5 stars
$5.54
+1.3%
$12.90
+132.9%
-43.0%$455.61M$78.12M-2.64230News Coverage

Related Companies and Tools

This page (NASDAQ:ABOS) was last updated on 7/21/2024 by MarketBeat.com Staff

From Our Partners